Psychosis: Goals of Pharmacotherapy

The immediate goals of acute antipsychotic treatment are to reduce agitation, enhance thought organization, and mitigate social withdrawal. These objectives address the most disruptive symptoms patients experience during acute psychotic episodes, helping restore basic functioning and improve quality of life during the critical early treatment phase.

Antipsychotic selection depends on the patient's clinical condition, potential drug interactions, and sensitivity to side effects. Clinicians must balance therapeutic efficacy against adverse effects like weight gain, metabolic concerns, and neurological symptoms. Individual patient factors and medical history guide whether typical or atypical agents are most appropriate.

Treatment adherence is challenging due to adverse drug events, cognitive impairment, substance misuse, and limited insight into illness. Patients may discontinue medication because side effects feel intolerable or they don't recognize their need for treatment. Long-acting injectable or depot antipsychotics can help prevent psychotic relapses in such cases.

Atypical antipsychotic agents generally exhibit similar or slightly improved efficacy to typical antipsychotics in treating schizophrenia, with some evidence suggesting advantages in addressing negative symptoms and cognitive deficits. Their primary distinction lies in a more favorable neurological side effect profile, though weight gain and metabolic concerns remain significant challenges.

In chronic conditions like schizophrenia and delusional disorder, extending antipsychotic treatment beyond the resolution of symptoms significantly reduces relapse rates. Long-term maintenance therapy, when properly adhered to, provides sustained symptom control and prevents the return of acute psychotic episodes that can destabilize patients' lives.

In treatment-refractory illness, where patients do not respond to standard drug treatments, options like clozapine or electroconvulsive therapy may be considered. Clozapine and olanzapine are used as a last resort due to their high metabolic risk. If no response occurs after two weeks, clinical reassessment including medication adherence evaluation should be undertaken.

Short-term treatment with low doses of high-potency typical or atypical agents effectively manages symptom exacerbation in delirium and dementia. For Parkinson's Disease Psychosis, atypical antipsychotics are preferred. Low doses minimize adverse effects while controlling behavioral disturbances in these vulnerable populations with complex medical conditions.